Corcept Therapeutics (NASDAQ:CORT) Stock Price Up 9.7% – Should You Buy?

Corcept Therapeutics Incorporated (NASDAQ:CORT)’s stock price shot up 9.7% during mid-day trading on Friday . The company traded as high as $37.15 and last traded at $38.1840. 785,728 shares were traded during trading, a decline of 61% from the average session volume of 2,037,837 shares. The stock had previously closed at $34.80.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Canaccord cut its price target from $140 to $99 but kept a “buy” rating — the firm still sees substantial upside versus current levels, which can support buying interest from some investors. Street Insider
• Neutral Sentiment: Unusually large options trading was reported around CORT, indicating elevated speculative interest and volatility but not a clear directional signal on fundamentals. Watch option volumes and open interest for clues to investor positioning. American Banking News – Options
• Negative Sentiment: FDA issued a Complete Response Letter for relacorilant, saying the application lacks sufficient evidence of effectiveness for treating hypercortisolism — the core catalyst for the prior collapse in valuation and the dominant near‑term risk to the stock. Yahoo Finance – CRL
• Negative Sentiment: Market coverage: multiple outlets (Zacks, Barron’s, Seeking Alpha, Fool) report the CRL drove a ~50% decline, prompted analyst downgrades/price‑target cuts, and cast doubt on Corcept’s near‑term pipeline value. This amplifies downside risk until Corcept outlines a credible path to new efficacy data or an appeal. Zacks – CRL
• Negative Sentiment: Coverage pieces and analyses explain the significance of the regulator’s concerns and why investors sold first and asked questions later — expect continued headline sensitivity and wide price swings. Barchart – FDA snub
• Negative Sentiment: Kaplan Fox & Kilsheimer launched an investigation into potential securities‑law violations tied to disclosures around relacorilant, adding legal and reputational risk that could prolong volatility and distract management. Globe & Mail / Kaplan Fox

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on CORT shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Corcept Therapeutics in a research note on Monday. UBS Group started coverage on shares of Corcept Therapeutics in a report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price objective on the stock. Wolfe Research downgraded Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price objective on the stock. in a research note on Wednesday. Zacks Research upgraded Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, December 15th. Finally, Canaccord Genuity Group lowered their target price on shares of Corcept Therapeutics from $140.00 to $99.00 and set a “buy” rating on the stock in a report on Friday. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $80.83.

Corcept Therapeutics Stock Performance

The business has a 50-day moving average of $77.14 and a two-hundred day moving average of $75.01. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.14 and a quick ratio of 3.07. The company has a market cap of $3.86 billion, a P/E ratio of 41.68 and a beta of 0.24.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.The business had revenue of $207.64 million for the quarter, compared to analysts’ expectations of $223.78 million. During the same quarter in the previous year, the firm posted $0.41 EPS. Corcept Therapeutics’s revenue was up 13.8% on a year-over-year basis. On average, sell-side analysts predict that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

Insiders Place Their Bets

In other Corcept Therapeutics news, insider Joseph Douglas Lyon sold 5,000 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $79.53, for a total transaction of $397,650.00. Following the transaction, the insider directly owned 10,277 shares of the company’s stock, valued at $817,329.81. This trade represents a 32.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Sean Maduck sold 20,000 shares of the stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $73.99, for a total value of $1,479,800.00. Following the completion of the transaction, the insider directly owned 7,904 shares of the company’s stock, valued at approximately $584,816.96. This represents a 71.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 196,700 shares of company stock worth $15,474,198. Company insiders own 20.80% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CORT. Pathstone Holdings LLC grew its holdings in shares of Corcept Therapeutics by 0.8% in the third quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company’s stock valued at $1,497,000 after purchasing an additional 144 shares in the last quarter. Huntington National Bank boosted its position in Corcept Therapeutics by 54.0% in the 2nd quarter. Huntington National Bank now owns 479 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 168 shares during the period. Focus Partners Wealth grew its stake in shares of Corcept Therapeutics by 0.5% in the first quarter. Focus Partners Wealth now owns 33,243 shares of the biotechnology company’s stock worth $3,797,000 after acquiring an additional 170 shares in the last quarter. Campbell Newman Asset Management Inc. grew its stake in shares of Corcept Therapeutics by 0.5% in the third quarter. Campbell Newman Asset Management Inc. now owns 35,530 shares of the biotechnology company’s stock worth $2,953,000 after acquiring an additional 170 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its position in shares of Corcept Therapeutics by 1.8% during the second quarter. Nisa Investment Advisors LLC now owns 9,951 shares of the biotechnology company’s stock worth $730,000 after acquiring an additional 180 shares during the period. 93.61% of the stock is currently owned by institutional investors and hedge funds.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.